Effects of Community-Based Cardiac Rehabilitation on Physical Function and Body Composition in Coronary Artery Disease: 1.5-Year Follow-Up

2012 ◽  
Vol 21 (8) ◽  
pp. 499-500
Author(s):  
S. Mandic ◽  
C. Hodge ◽  
E. Stevens ◽  
H. Horwood ◽  
R. Walker ◽  
...  
2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Sandra Mandic ◽  
Claire Hodge ◽  
Emily Stevens ◽  
Robert Walker ◽  
Edwin R. Nye ◽  
...  

Objective. To examine long-term changes in physical function and body composition in coronary artery disease (CAD) patients participating in ongoing community-based cardiac rehabilitation (CR).Design. Thirty-four individuals (69.7±8.2years; 79% men) participated in this longitudinal observational study. Baseline and follow-up assessments included incremental shuttle walk, short physical performance battery, handgrip strength, chair stands, body composition, last year physical activity, and CR attendance.Results. Participants attended38.5±30.3%sessions during1.6±0.2year followup. A significant increase in 30-second chair stands (17.0±4.7to19.6±6.4,P<0.001), body weight (75.8±11.1to77.2±12.1 kg,P=0.001), and body fat (27.0±9.5to29.1±9.6%,P<0.001) and a decline in handgrip strength (36.4±9.4to33.0±10.6kg·f,P<0.001) and muscle mass (40.8±5.6to39.3±5.8%,P<0.001) were observed during followup. There was no significant change in shuttle walk duration. CR attendance was not correlated to observed changes.Conclusions. Elderly CAD patients participating in a maintenance CR program improve lower-body muscle strength but experience a decline in handgrip strength and unfavourable changes in body composition, irrespective of CR attendance.


Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Abdulhamied Alfaddagh ◽  
Francine K Welty

Introduction: Poor physical function impairs fitness and is associated with worse cardiovascular outcomes and all-cause mortality. Arthritis and joint dysfunction limit physical function in coronary artery disease (CAD) patients. Hypothesis: Omega-3 fatty acids (FA) improve physical function in CAD patients through reducing inflammation. Methods: We randomized 249 subjects with stable CAD to 3.6 of omega-3 FA (1.86 g of eicosapentaenoic acid + 1.5 g of docosahexaenoic acid) per day or no omega-3 (control) for one year. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) was used to evaluate pain, stiffness and physical function at baseline and one year follow-up. Inflammation was assessed by total white blood cell (WBC) count and its subsets as well as urine microalbumin-creatinine ratio (MCR). Results: Mean age was 63.0 ± 7.58 years; 17% were women. Controls had worsening stiffness (% Δ = 8.4%; p = 0.036) at 1 year follow-up while those on omega-3 FA had no change (% Δ = 0.4%, p = 0.886 - see Table)(a lower percent change indicates better functioning). Compared to controls, those on omega-3 FA had better physical function (% Δ = 8.5% vs. -2.8%, p = 0.011), and total WOMAC scores (% Δ = 7.8% vs. -2.5%, p = 0.011) and a significant decrease in WBC (% Δ = -3.5 vs. -9.4%; p=0.009) and neutrophils (% Δ = -3.5% vs. -11.6%; p=0.005) at one year follow-up. MCR significantly worsened only in the control group (% Δ = 53.3%, p = 0.037) at one year follow-up (p-value for control vs. omega-3 FAs groups = 0.026). Monocytes were decreased in the omega-3 FAs group at one year compared to baseline (% Δ = -11.1%, p < 0.001) and directly correlated with physical function and total scores (p = 0.033 and p = 0.024, respectively). Conclusions: Omega-3 FAs attenuate worsening of physical function over a one year period in CAD patients possibly mediated through an anti-inflammatory effect. Therefore, omega-3 FA may benefit CAD patients by improving their physical function.


Author(s):  
Joseph Ladapo ◽  
David Sharp ◽  
Bruce Maniet ◽  
Linda Ross ◽  
John Blanchard ◽  
...  

Background: Patients with symptoms suggestive of obstructive coronary artery disease (CAD) frequently undergo unnecessary testing and procedures. Approximately $5.9 billion/year is spent on non-invasive and invasive testing in the US in the non-diabetic population without a prior revascularization or myocardial infarction, yet some patients continue to be misdiagnosed. A previously validated blood-based, gene expression diagnostic test with a 96% NPV can facilitate determination of the current likelihood of CAD in a symptomatic patient. Objective: The objective of the study is to evaluate the use of the gene expression score (GES) and its effect on clinician risk stratification of patients considered for referral to cardiology in a community-based cardiovascular registry. Methods: The prospective PRESET Registry (NCT01677156) will enroll 1,000 stable, non-acute adult patients without a history of CAD from 21 US primary care practices. Primary care clinicians provide the pre- and post-GES diagnosis and evaluation plan for each patient. Demographics, clinical factors, and GES results (predefined as low [GES ≤15] or elevated [GES >15]) are collected, as well as treatment plans, diagnostic tests performed and results, and referrals to cardiology and advanced cardiac testing. Clinician and patient quality of care measures, such as satisfaction with care, are being assessed. Results: In an interim cohort of 393 patients, 199 (50.6%) were women, the median age was 55 years with 116 (29.5%) age ≥65, and the median BMI is 29.8. The median GES was 17 (range, 1-40) and 177 patients (45.0%) had low scores. In this analysis, 19 of 177 (10.7%) patients with low scores were referred to cardiology, while 105 of 216 (48.6%) patients with elevated scores were referred (OR 7.87, p<0.0001). At 30 day follow-up, no MACE were reported in patients with low scores. Longer-term follow-up is underway. Conclusion: In this interim analysis of a community-based cardiovascular registry evaluating patterns of care among patients presenting with symptoms suggestive of obstructive CAD, a personalized medicine, gene-expression based test was adopted in clinical practice and was associated with a statistically significant and clinically relevant effect on medical decision making. In conclusion, use of the GES test showed clinical utility in efficiently and safely ruling out obstructive CAD, minimizing referral of low risk patients to cardiology.


2021 ◽  
Vol 41 (4) ◽  
pp. 1558-1569
Author(s):  
Vlad C. Vasile ◽  
Jeffrey W. Meeusen ◽  
Jose R. Medina Inojosa ◽  
Leslie J. Donato ◽  
Christopher G. Scott ◽  
...  

Objective: Cardiovascular disease remains a leading cause of mortality worldwide. Ceramide scores have been associated with adverse outcomes in patients with established coronary artery disease. The prognostic value of ceramide score has not been assessed in the general population. We tested the hypothesis that ceramide scores are associated with major adverse cardiac events (MACE) in a community-based cohort with average coronary artery disease burden at enrollment. Approach and results: In a prospective community-based cohort, we performed passive follow-up using a record linkage system to ascertain the composite outcome of MACE, defined as acute myocardial infarction, coronary revascularization (bypass grafting or percutaneous intervention), stroke, or death. Ceramides were analyzed as log-transformed continuous variables, ratios or scores, and quartiles with adjustment for confounders. We analyzed 1131 subjects, 52% females, mean age±(SD) 64±9 years. After a median follow-up of 13.3 years (Q1, 12.7; Q3, 14.4), 486 patients experienced a MACE: myocardial infarction (80), coronary artery bypass surgery (34), percutaneous coronary intervention (62), stroke (94), and all-cause death (362). Ceramide ratios were significantly associated with MACE independently of LDL-c (low-density lipoprotein cholesterol) and conventional coronary artery disease risk factors. Those in the highest quartile of ceramide score had nearly 1.5-fold risk of MACE, hazard ratio, 1.47 (95% CI, 1.12–1.92). There was a dose-response association across quartiles of ceramide ratios and MACE. Conclusions: Elevated ceramide score is a robust predictor of cardiovascular disease and MACE in the community. The risk conferred by the ceramide score has a dose-response behavior and is independent of conventional risk factors.


Sign in / Sign up

Export Citation Format

Share Document